Abstract :
The burden of dermatological conditions is huge on the global health accounting for 44.1 million DALYs worldwide. Impetigo is a highly contagious bacterial infection with 2.5 time’s greater likelihood in pediatrics (12.3%) than in adults (4.9%). Micro-organisms causing impetigo include bacteria like or both. The management of Impetigo is with topical and systemic antimicrobial agents. Topical antimicrobial resistance is on the rise in patients with Impetigo. Therefore, there is clearly a need for newer antimicrobials having different mode of action and showing good activity against non-responding strains in the management of impetigo. Ozenoxacin is a novel, topical quinolone with a good safety and tolerability profile in the management of Impetigo. The authorizing bodies namely USFDA, European Medical Agency, and DCGI have approved the use of Ozenoxacin 1% cream for the topical treatment of impetigo due to in adult and pediatric patients 2 months of age and older.
Keyword :
Impetigo; Staphylococcus, Streptococcus, Ozenoxacin